Previous studies using stearoyl-CoA desaturase–1–deficient (SCD1-deficient) mice have shown that this enzyme plays an important role in many diseases of altered cellular metabolism including obesity, insulin resistance, and dyslipidemia. Although SCD1 activity is highest in lipogenic tissues such as the liver and adipose tissue, it is also present at lower levels in most tissues. To better understand the role of SCD1 in liver metabolism it is necessary to explore SCD1 deficiency in more focused, tissue-specific manner. This commentary focuses on 2 recent studies published in the *JCI* that address this question using antisense oligonucleotide inhibition of SCD1. First, Jiang et al. have previously reported that long-term inhibition of SCD1 prevents the development of high-fat diet–induced obesity and hepatic steatosis. Second, Gutiérrez-Juárez et al. show in this issue that short-term inhibition of hepatic SCD1 is sufficient to prevent diet-induced hepatic insulin resistance, signifying an important role of hepatic SCD1 in liver insulin sensitivity (see related article beginning on page 1686).

Stearoyl-CoA desaturase (SCD) is the central lipogenic enzyme catalyzing in vivo reactions in the synthesis of monounsaturated fatty acids (MUFA.s), particularly oleate (C18:1n–9) and palmitoleate (C16:1n–7), which are the major MUFA.s of membrane phospholipids, triglycerides (TGs), wax esters, and cholestereryl esters. Recent studies of SCD1 have yielded many new insights into the biology of lipid metabolism and have demonstrated that mice with a global deletion of Scd1 (Scd1−/− mice) are resistant to high-fat diet–induced obesity and glucose intolerance (1). Scd1−/− mice also have increased hepatic fatty acid oxidation and decreased lipogenic gene expression (1). Furthermore, Scd1−/− mice exhibit increased thermogenesis and insulin signaling in skeletal muscle and brown adipose tissue (2–4). Currently the mechanisms leading to the phenotypes due to SCD deficiency or overexpression in different tissues are not understood; yet the findings so far reveal that SCD1 is an important metabolic control point in lipid metabolism and is a promising drug target for the treatment of the metabolic syndrome.

**Can obesity and symptoms of the metabolic syndrome be alleviated by inhibition of SCD1?**

In vivo antisense oligonucleotide (ASO) reduction of target genes is a powerful tool for
identifying novel metabolic drug targets and further elucidating the role of various genes in cellular metabolic pathways. The use of ASO-mediated inhibition in adult mice also allows for manipulation of gene expression of targets that are necessary during embryonic development. This is exemplified by recent studies investigating ASO-mediated inhibition of acetyl-CoA carboxylase 1 (ACC1) and acyl-CoA:diacylglycerol acyltransferase 2 (DGAT2) (5, 6). In these studies, ASO-mediated inhibition circumvented the challenge of the lethality caused by whole-body deletion of Acc1 or Dgat2 (7, 8).

ASO-mediated inhibition strategies are also currently being employed for providing further mechanistic insight into results previously observed in whole-body Scd1–/– gene knockout studies. Similar to the results obtained in Scd1–/– mice, Jiang et al. reported that ASO-mediated inhibition of Scd1 in C57BL/6j mice resulted in resistance to high-fat diet-induced obesity and hepatic steatosis (9). These animals also had lower postprandial glucose and insulin levels, increased oxygen consumption, increased physical activity, and reduced lipogenic gene expression (Figure 1). A benefit of this ASO-mediated approach is that it avoids the deleterious effects of Scd1 deficiency in tissues such as the skin, which results in alopecia and skin abnormalities. Although more localized than global deletion of a gene, i.p. delivery of ASO inhibitors does not allow for the unequivocal determination of the tissue-specific role of target genes because i.p. injection of Scd1-targeted ASOs caused decreased Scd1 gene expression in brown and white adipose tissue as well as in liver (9, 10) and possibly in other unidentified tissues.

Unlike the previous studies by Jiang et al. (9), which involved a 10-week ASO-mediated treatment and high-fat (lard) diet feeding, the studies reported by Gutiérrez-Juárez et al. in this issue of the JCI (10) focused on the early stages of hepatic insulin resistance elicited by a shorter-term feeding of a high-fat diet. In these studies the metabolic consequences of ASO-mediated inhibition of Scd1 were investigated prior to changes in body weight, which occur with longer feeding periods. Whereas control mice and rats have increased hepatic glucose production and decreased insulin-mediated inhibition of hepatic glucose production when fed the high-fat diet, animals treated with the Scd1-targeted ASO are resistant to these diet-induced effects (Figure 1). Therefore, these studies clearly illustrate that hepatic Scd1 activity is involved in the development of diet-induced hepatic insulin resistance in these animals.

**Do dietary and de novo MUFAs interact to regulate metabolism?**

Scd1 deficiency poses an interesting physiological question. The primary lipogenic tissues such as liver and white adipose tissue synthesize MUFAs via Scd1. These tissues subsequently release MUFAs into the circulation via lipoprotein cholesteryl esters, TGs, and phospholipids and also as free fatty acids. In Scd1–/– mice and in i.p. Scd1-targeted ASO-treated mice and rats, the contribution of liver and adipose tissue to MUFA production is severely inhibited and there is decreased exposure of other periph-

---

**Figure 1**

Metabolic effects elicited by inhibition of Scd1 by ASOs. The inhibition of Scd1 in rodents with ASOs has been shown to prevent many high-fat diet–induced metabolic complications. i.p. delivery of Scd1 ASO results in decreased Scd1 expression in liver and adipose in both short-term (A) and long-term treatment periods (B). In studies by Gutiérrez-Juárez et al., short-term treatment (5 days) with i.p. Scd1 ASO prevented diet-induced insulin resistance (10) (A). In these studies, short-term liver-specific intraportal Scd1 ASO treatment also elicited these effects (A). Long-term treatment (4–10 weeks) with i.p. Scd1 ASO prevents diet-induced obesity and hepatic steatosis (9) (B). Adipose-specific inhibition as well as long-term liver-specific inhibition of Scd1 remain to be explored (A and B).
eral tissues to circulating MUFAs derived from de novo synthesis. In the situation of liver-specific SCD1 inhibition as achieved by intraportal ASO delivery in the studies of Gutiérrez-Juárez et al. (10), adipocyte-derived MUFAs would potentially influence the fatty composition of the liver. Despite the availability of MUFAs from adipose tissues as well as from the oleate-rich lard diet, liver-specific SCD1 inhibition elicited effects on hepatic insulin signaling (10). Since previous studies of the role of SCD1 on insulin signaling were mostly based on the chronic effects observed in Scd1−/− mice, the observations from Gutiérrez-Juárez et al. provide a direct link between SCD1 deficiency and the improvement of insulin action in liver (10).

Surprisingly, the hepatic TG phenotype observed differs among the studies of Gutiérrez-Juárez et al. (10), those of Jiang et al. (9), and studies using Scd1−/− mice (1, 11). Where as a 10-week treatment of mice with Scd1-targeted ASO and high-fat diet resulted in reduced hepatic steatosis, the current study shows that short-term treatment with Scd1-targeted ASO results in increased hepatic TG levels relative to both high-fat- and standard chow-fed animals treated with the control ASO. This suggests that improved insulin signaling due to SCD1 deficiency may occur in the absence of decreased cellular TG levels. A potential mechanism for the increased hepatic TG levels is the acute enhancement of insulin signaling. The overfed SCD1 ASO group displayed increased Akt phosphorylation and dramatic suppression of glucose-6-phosphatase and phosphoenolpyruvate carboxykinase gene expression relative to both the standard chow and overfed control ASO groups. This alteration in insulin signaling could affect both the synthesis and the secretion of hepatic TGs. Decreased hepatic glucose cycling due to transcriptional repression of gluconeogenic genes and the stimulatory effect of insulin signaling on glycolysis may augment the conversion of glucose and gluconeogenic precursors into acetyl-CoA for de novo fatty acid synthesis. However, the levels of the lipogenic enzymes ACC and fatty acid synthase were not increased and tended to be lowered by Scd1-targeted ASO treatment relative to the other groups (10). Additionally, decreased hepatic SCD1 expression in the SCD1 ASO group should result in decreased production of MUFAs, which are the preferred substrate for TG production (11). It is possible that the partial repression of SCD1 activity by ASO-mediated inhibition is permissive for hepatic TG synthesis due to adequate MUFA production, unlike the Scd1−/− mouse, which has a more severe reduction in MUFA synthesis.

The accumulation of hepatic TGs may also be due to increased insulin-mediated inhibition of VLDL-TG secretion. Hepatic insulin signaling decreases VLDL-TG secretion, and dysregulation of this mechanism contributes to the dyslipidemia observed in insulin-resistant states (12). Thus increased insulin signaling elicited by hepatic SCD1 deficiency may decrease both hepatic glucose and VLDL-TG output, resulting in hepatic accumulation of TGs. Additionally, there may be species differences between rats and mice that influence how SCD1 deficiency influences metabolism. Although the mechanism by which SCD1 deficiency improves insulin signaling is not known, Gutiérrez-Juárez et al. found that Scd1-targeted ASO treatment decreased hepatic protein tyrosine phosphatase 1B (PTP1B) protein levels, which was similar to the decrease observed in the muscle of Scd1−/− mice (2, 10). These data suggest that SCD1 and/or its product MUFAs may directly regulate PTP1B expression. Future experiments will be required to address this hypothesis. In contrast to the increased level of AMP kinase (AMPK) phosphorylation observed in the livers of Scd1−/− mice (13), short-term treatment with Sd1-targeted ASOs did not affect AMPK phosphorylation (10), suggesting that increased insulin sensitivity by SCD1 deficiency may be independent of AMPK activation.

Although Gutiérrez-Juárez et al. show that treatment with Scd1-targeted ASOs restores the ability of insulin to suppress hepatic glucose production in overfed animals, this study did not determine whether metabolic differences are also observed in chow-fed animals (10). Scd1−/− mice are not only resistant to many high-fat diet–induced phenomena that develop in wild-type animals with normal SCD1 activity, but also display numerous metabolic changes in liver, adipose tissue, and muscle when maintained on a chow diet (1–4, 11, 13). Therefore, future studies will be necessary to address a key unsettled issue of the role of SCD1 in hepatic insulin signaling. Is hepatic SCD1 deficiency elicited by ASO-mediated inhibition of SCD1 only preventative for the onset of diet-induced hepatic insulin resistance, or does hepatic SCD1 deficiency also augment insulin signaling relative to control animals in the absence of a dietary stress? **SCD1 inhibition: where, how much, and for how long?**

Many questions remain in the elucidation of the tissue-specific role of SCD1. First, where is SCD1 deficiency most important for eliciting metabolic effects? The current studies by Gutiérrez-Juárez et al. suggest that hepatic SCD1 deficiency alone is sufficient to enhance hepatic insulin sensitivity (10). However, the inability of the i.p. ASO-mediated inhibition of SCD1 to enhance whole-body glucose uptake suggests that SCD1 expression in tissues other than liver and adipose also contribute to enhancing the action of insulin. SCD1 expression in muscle may be most important for this phenotype, since this tissue is the major site of glucose disposal. In support of this hypothesis, increased expression of SCD1 in skeletal muscle causes abnormal lipid metabolism and may contribute to the onset of obesity and insulin resistance in humans (14). The correlation of SCD1 activity with metabolic phenotypes highlights another key question. How much SCD1 deficiency is necessary to elicit local or whole-body metabolic changes? Although Scd1−/− mice have pronounced phenotypes relative to Sd1−/− animals, current SCD1 ASO studies suggest that partial SCD1 deficiency also alters metabolism.

More research is also needed to determine the tissue-specific contribution of SCD1 in controlling other phenotypes observed in Scd1−/− mice, such as resistance to diet-induced obesity, increased metabolic rate, and increased food intake. Additionally, how long is SCD1 deficiency required to elicit metabolic effects? Would liver-selective SCD1 inhibition by intraportal ASO delivery elicit resistance to obesity in long-term diet studies, or are extrahepatic tissues more important for this phenotype? If not, would hepatic insulin sensitivity persist in an obese animal with liver-selective deficiency of SCD1? Although the current studies did not detect a difference in whole-body glucose disposal, they were performed under conditions of controlled hyperinsulinemia. The role of SCD1 expression in various tissues, including the pancreatic β cell, in regulating insulin secretion is not understood. Thus a glucose tolerance test or similar assessment that demands endogenous insulin secretion would be necessary to determine the overall physiological contribution of SCD1 deficiency to whole-body glucose disposal.

In summary, the complications of the metabolic syndrome are intimately related to the dysregulation of lipid metabolism in various tissues. Among the many tissues involved, the liver and adipose are responsible for integrating many complimentary and sometimes conflicting meta-
In this issue of the JCI, the observation of the altered pathogenicity of a Cryptococcus neoformans glucosylceramide (GlcCer) mutant shines new light on the initiation of cryptococcal infection. Rittershaus and colleagues demonstrate that the cell surface glycosphingolipid GlcCer is essential for the fungus to grow in the extracellular environments of the host bloodstream and alveolar spaces of the lung, which, in contrast to the acidic intracellular environment of macrophages, are characterized by a neutral pH (see the related article beginning on page 1651). Their findings establish an unexpected connection between this glycosphingolipid and the fungal responses to physiological CO₂ and pH. They also focus new attention on the therapeutic potential of anti-GlcCer antibodies found in convalescent sera.

Cryptococcus neoformans is among the few fungal pathogens with well-defined virulence factors, including a polysaccharide capsule and a melanin coat (1). The recent past has witnessed the identification of many new genes that impact C. neoformans virulence, and in most cases the new genes ultimately govern those known virulence factors. A report from Rittershaus, Del Poeta, and colleagues in this issue of the JCI (2) is thus surprising in that it establishes that a new virulence regulator does not act through any previously known virulence traits, but through a connection between lipid-mediated signaling and the pathogen’s response to the CO₂ levels and pH of host tissue. The report provides intriguing new insight into the natural infection process and points to the potential therapeutic significance of an antifungal antibody response.

The connection between GlcCer and Cryptococcus neoformans virulence C. neoformans is an opportunistic pathogen that causes disseminated infection and meningocencephalitis in immunocompromised hosts, especially those with AIDS (1). Its close relative, Cryptococcus gattii, is a primary pathogen that caused an outbreak recently on Vancouver Island (3, 4). Infection begins with inhalation of airborne spores or yeast cells. The organism is eventually phagocytosed by macrophages, in which it survives as an intracellular pathogen (5). Rittershaus and colleagues show that the poorly understood events that occur between inhalation and macrophage phagocytosis depend upon cryptococcal synthesis of the sphingolipid glucosyleceramide (GlcCer) (2).

GlcCer is found at the surface of C. neoformans cells and accumulates at the neck between the mother cell and the emerging daughter cell. In order to determine the function of GlcCer, the authors created a mutant C. neoformans strain lacking GlcCer synthase 1 (Gcs1), which they rigorously show to be encoded by the gcs1 gene (2). This Δgcs1 mutant had an unusual phenotype: it was completely avirulent in mice following nasal inhalation, yet caused lethal infection when delivered through intravenous injection (Figure 1). The inhaled organisms

Cryptococcal virulence: beyond the usual suspects

Aaron P. Mitchell
Department of Microbiology, Columbia University, New York, New York, USA.

Nonstandard abbreviations used: Gcs; glucosylceramidase synthase; GlcCer, glucosylceramide.

Conflict of interest: The author has declared that no conflict of interest exists.

Citation for this article: J Clin Invest. 116:1481–1483 (2006). doi:10.1172/JCI28842.